source
- J&J lines up $2.58B option to buy Sail, Flagship's in vivo CAR-T biotechThe in vivo CAR-T space is getting more competitive as one of the biggest cell therapy players expands its role. Johnson & Johnson is paying $785 million upfront to work with Flagship Pioneering's…Endpoints · 54m ago↗ source
- FDA reviewers doubt Replimune’s melanoma therapy as shares tumble 40%Replimune's shares fell nearly 40% after FDA reviewers released briefing documents expressing skepticism about its experimental melanoma drug RP1. RP1 has been rejected twice before; the company l…